MicroRNA-765 enhances the anti-angiogenic effect of CDDP via APE1 in osteosarcoma

29Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

Human osteosarcoma (HOS) is the most common malignancy in children and adolescents and has a heterogeneous presentation and high mortality. Previous studies have shown that microRNAs contribute to RNA silencing and post-transcriptional regulation of gene expression. Here, we showed that significantly increased expression of miR-765 with or without CDDP (Cisplatin) down-regulates APE1 expression and angiogenesis-related markers (VEGF, FGF2, TGFβ, and CD34). Further investigation showed that miR-765 modulates osteosarcoma cell migration and angiogenesis following treatment with cisplatin in vitro and in vivo. MiR-765 increases the anti-angiogenic effect of CDDP in human osteosarcoma. Elucidation of the mechanism of the miR-765-APE1 axis in tumor progression of HOS will be beneficial in identifying biomarkers and therapeutic target of osteosarcoma.

Cite

CITATION STYLE

APA

Liang, W., Wei, X., Li, Q., Dai, N., Li, C. Y., Deng, Y., … Zhong, Z. Y. (2017). MicroRNA-765 enhances the anti-angiogenic effect of CDDP via APE1 in osteosarcoma. Journal of Cancer, 8(9), 1542–1551. https://doi.org/10.7150/jca.18680

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free